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 ing that the transfected cells are sensitive to
 the lethal effects of TNF-ot (Fig. 3). How-
 ever, a dose-dependent increase in cell sur-
 vival was seen when RelA was provided,
 with virtually complete protection at the
 highest dose (Fig. 3). Thus, expression of
 RelA prevents cell death by TNF-ot in cells
 that developed in a ReIA-1- animal.
 Our previous studies have demonstrated
 an essential role for RelA in hepatocyte sur-
 vival (7). Interestingly, detectable amounts
 of TNF-cx are present by mouse embryonic
 day 9 (19). The results presented here sug-
 gest that TNF-ao produced by cells of hema-
 topoietic origin in the fetal liver may affect
 hepatocyte survival. Conversely, RelA may
 be required for protection from a cell-au-
 tonomous killing mechanism operating in
 hepatocytes.
 Recent studies have identified genes
 that are involved in transducing TNF-ot
 death signals (16, 20-22). However, the
 cytotoxic effects of TNF-a on most cells are
 only evident if RNA or protein synthesis is
 inhibited, suggesting that de novo RNA or
 protein synthesis protects cells from TNF-a
 cytotoxicity, probably by induction of pro-
 tective genes (23, 24). It would appear that
 TNF-ot transmits one signal eliciting cell
 death and another, dependent on RelA,
 that protects against death by induction of
 gene expression. Consistent with this hy-
 pothesis, we have found that one such anti-
 apoptotic gene, A20 (25), is induced in
 RelA+1+ 3T3 cells after TNF-ot treatment
 but is not induced in ReIA-1- 3T3 cells
 (9). However, transfection of A20 into
 Re1A-1- 3T3 cells is unable to prevent cell
 death (9), suggesting that other genes (or
 multiple genes) may be required to protect
 cells from TNF-cx cytotoxicity.
 The results presented here, and in ac-
 companying papers (26, 27), indicate an
 intriguing role for NF-KB in cell survival
 that may provide additional therapeutic ap-
 proaches against both inflammatory and
 proliferative diseases. TNF-ot produced by
 infiltrating leukocytes is a key modulator of
 inflammation (28, 29). Interestingly, two
 widely used anti-inflammatory drugs, salicy-
 lates and glucocorticoids, are both inhibi-
 tors of NF-KB (30-32), although it is pres-
 ently unclear whether NF-KB inhibition by
 these drugs results in killing of potentially
 inflammatory cells. Additionally, if tumor
 cell sensitivity to TNF-ot is controlled by
 NF-KB, a combination of NF-KB inhibitors
 and TNF-ot may result in a dramatic en-
 hancement of killing over TNF-ot alone.
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 TNF- and Cancer Therapy-lnduced Apoptosis:
 Potentiation by Inhibition of NF-KB
 Cun-Yu Wang, Marty W. Mayo, Albert S. Baldwin Jr.*
 Many cells are resistant to stimuli that can induce apoptosis, but the mechanisms
 involved are not fully understood. The activation of the transcription factor nuclear
 factor-kappa B (NF-KB) by tumor necrosis factor (TNF), ionizing radiation, or dauno-
 rubicin (a cancer chemotherapeutic compound), was found to protect from cell killing.
 Inhibition of NF-KB nuclear translocation enhanced apoptotic killing by these reagents
 but not by apoptotic stimuli that do not activate NF-KB. These results provide a
 mechanism of cellular resistance to killing by some apoptotic reagents, offer insight
 into a new role for NF-KB, and have potential for improvement of the efficacy of cancer
 therapies.
 Observations that NF-KB (1) is activated by
 certain apoptotic stimuli has led to the spec-
 ulation that this transcription factor may me-
 diate aspects of programmed cell death. An
 anti-apoptotic function of NF-KB is also sug-
 gested, however, because mice that lack the
 NF-KB p65/RelA gene die embryonically from
 extensive apoptosis within the liver (2). Many
 cells that respond to TNF, a strong activator
 of NF-KB, are also resistant to cell killing,
 which is enhanced in the presence of protein
 synthesis inhibitors (3). We investigated,
 therefore, whether the transcription factor
 NF-KB is protective against apoptotic killing
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 induced by TNF in a model cell system. We
 initiated our studies using the human fibrosar-
 coma cell line HT1080, which is relatively
 resistant to killing by TNF (4). To potentially
 block the activation of NF-KB in response to
 TNF stimulation, we established an HT1080
 cell line (HT1080I) expressing a super-repres-
 sor form of the NF-KB inhibitor IKBot. The
 super-repressor IKBot contains serine-to-ala-
 nine mutations at residues 32 and 36, which
 inhibit signal-induced phosphorylation (5)
 and subsequent proteasome-mediated degra-
 dation of IKBa (6). This mutant IKBot protein
 acts as a super-repressor because it binds to
 NF-KB and inhibits DNA binding as well as
 nuclear translocation but is unable to respond
 to cellular signals such as those induced by
 TNF (5, 6). A control line (HT108OV) was
 established that contained the empty vector
 and the hygromycin selectable marker. TNF-
 a-induced NF-KB activation, as measured by
 DNA binding of nuclear extracts, was effec-
 tively blocked by the super-repressor IKBao in
 HT1080I cells as compared with activation in
 the control cell line [(4) and below].
 TNF-ao is more effective at inducing apop-
 tosis in the IKBot super-repressor-expressing
 cells (HT1080I) than in the control cell line
 (HT108OV) (Fig. 1A). Similar results were
 obtained with pooled clones of HT1080V or
 HT1080I cells (4), which indicates that the
 results we obtained were because of the over-
 expression of the super-repressor IKBoX and
 were not due to clonal variation. That cells
 were killed by apoptosis was confirmed by
 the use of the deoxynucleotidyl transferase-
 mediated dUTP nick end labeling (TUNEL)
 assay, which measures DNA strand breaks
 and is diagnostic for cells undergoing apop-
 tosis. Apoptosis was observed only in the
 HT1080I cells treated with TNF (Fig. 1B).
 Other cells were more sensitive to TNF-ao
 killing when the IKBa super-repressor was
 expressed, which shows that the results were
 not unique to the HT1080 cells (4). Thus,
 expression of a super-repressor form of IKBot
 potently enhanced the ability of TNF to
 initiate apoptosis in a variety of cells that are
 normally resistant to this cytokine, which
 suggests that the activation of NF-KB by
 TNF is protective.
 To exclude the possibility that the ex-
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 pression of the super-repressor form of I KBoX
 leads to a function that is different from the
 inhibition of NF-KB, we confirmed the re-
 quirement for NF-KB in inhibition of TNF-
 induced apoptosis. The pretreatment of
 HT1080V cells with interleukin-1 (IL-1, an
 activator of NF-KB that does not initiate
 apoptosis) blocked the subsequent killing of
 these cells induced by combined cyclohex-
 imide (CHX) and TNF treatment (Fig.
 2A). As a control and to determine that it
 was NF-KB that was responsible for the
 protection, we found that IL-1 had no pro-
 tective effect on the HT1080I cell line, in
 which NF-KB activation is blocked (4) by
 the expression of the super-repressor I KBa
 (Fig. 2A). IL-1 is known to block TNF-
 mediated killing (3). We determined
 whether a proteasome inhibitor would en-
 hance cell killing of HT1080 cells in re-
 sponse to TNF treatment, because the deg-
 radation of IKBao is controlled by the pro-
 teasome after inducible phosphorylation
 and subsequent ubiquitination (6). Protea-
 some inhibitors of the peptide aldehyde cat-
 egory are potent inhibitors of NF-KB acti-
 vation (6). In a dose-dependent fashion,
 the proteasome inhibitor MG132 (Z-Leu-
 Leu-Leu-H) strongly enhanced the killing
 of HT1080V cells in response to TNF (4).
 If NF-KB inhibition was critical for making
 cells vulnerable to TNF killing, then overex-
 pression of NF-KB subunits should restore pro-
 tection against cell killing in the HT1080I
 model. We transfected vectors encoding the
 p50 and RelA/p65 subunits of NF-KB or the
 empty cytomegalovirus (CMV) vector control
 into the HT1080I cells and stimulated them
 with TNF. As expected, the vector alone did
 not provide protection against cell killing in-
 duced by TNF (Fig. 2B). However, expression
 of the NF-KB p50 and RelA/p65 subunits
 provided protection against TNF-induced ap-
 optosis, indicating that it is NF-KB that is
 blocked by the super-repressor IKBot and that
 NF-KB expression blocks programmed cell
 death. Additional evidence that NF-KB is re-
 quired for protection against cell killing in-
 duced by TNF is shown by the fact that
 embryonic fibroblasts from RelA/p65 null
mice (2) are killed by TNF with a much
 higher frequency than are those from wild-
 type animals (4, 7).
 Many cancer therapies function to kill
 transformed cells through apoptotic mecha-
 nisms; resistance to apoptosis provides protec-
 tion against cell killing initiated by these ther-
 apies (8). To determine if other apop-
 totic stimuli activate NF-KB and whether NF-
 KB is protective against these stimuli, we an-
 alyzed ionizing radiation-, daunorubicin-, and
 staurosporine-treated cells. Ionizing radiation
 is known to activate NF-KB in several cell
 types (9). We therefore investigated whether
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 Fig. 1. Expression of the super-repressor IKBa over-
 comes the block to TNF-mediated apoptosis. (A)
 HT1080 fibrosarcoma cells were cotransfected with the pCMV empty vector or with same vector
 containing a cDNA encoding the super-repressor IKBa and with the pCEP4 vector for hygromycin B
 selection (400 ,ug/ml). Transfection was by the lipofectamine protocol (Gibco/BRL). HT1 0801 expresses
 the super-repressor IKBa, and HT1080V contains the empty expression vector. IKBa levels were
 determined by immunoblotting (ECL, Amersham) of equivalent amounts of protein from the different
 cells with an antibody to human IKBa (Rockland, Boyertown, Pennsylvania). Expression of the super-
 repressor IKBa in HT1080 cells efficiently blocked TNF-stimulated NF-KB nuclear translocation, as
 determined by electrophoretic mobility-shift assay (EMSA) (4). Either HT1 080V cells (open squares) or
 HT1 0801 cells (solid diamonds) were treated with TNF-a (20 ng/ml) for varying times, and surviving cells
 were quantified by crystal violet assay (19). Data shown are the mean of three independent experi-
 ments ? SD, and the percentage cell survival was defined as the relative number of TNF-treated versus
 untreated cells. (B) Detection of TNF-induced apoptosis by TUNEL staining (20). HT1 080V (V) or
 HT1 0801 (1) cells were either untreated (-TNF) or were stimulated (+TNF) with TNF-a (50 ng/ml) for 7
 hours and then fixed with 4% paraformaldehyde. The staining was done according to the manufactur-
 er's instructions (Boehringer Mannheim). Positive cells show the condensed morphology typical of
 apoptotic cells.
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 ionizing radiation, the chemotherapeutic
 compound daunorubicin, and staurosporine
 activated NF-KB in the HT1080V cells and in
 the HT1080I cells. Both daunorubicin and
 ionizing radiation activated NF-KB (Fig. 3A).
 HT1080I cells were blocked by these two
 stimuli in their ability to activate NF-KB (Fig.
 3A), which is consistent with the expression
 of the super-repressor IKBot. In contrast, stau-
 rosporine was not effective at NF-KB activa-
 tion (Fig. 3A). We then tested whether ion-
 izing radiation-, daunorubicin-, and stauro-
 sporine-induced cell killing can be enhanced
 by the inhibition of NF-KB activity. For these
 experiments, we used the HT1080V control
 fibrosarcoma cells and the HT1080I deriva-
 tive that expresses the super-repressor form of
 IKBot. Apoptotic stimuli that induce NF-KB,
 namely daunorubicin (Fig. 3B) and ionizing
 radiation (Fig. 3C), are enhanced in their
 ability to kill the HT1080I cells. However,
 apoptosis induced by staurosporine is not en-
 hanced by the expression of IKBat (4), which
 is consistent with the observation that stau-
 rosporine does not effectively activate NF-KB
 (Fig. 3A). Thus, the activation of NF-KB is
 part of the cellular response to a variety of
 genotoxic agents, and under stress-induced
 conditions, this transcription factor provides
 significant protection against apoptosis.
 Our data indicate that the activation of
 NF-KB by TNF, ionizing radiation, and
 daunorubicin provides protection against
 apoptotic cell killing induced by these stimuli.
 Distinct signaling pathways initiated by TNF
 engagement of its receptor lead to activation
 of both apoptosis and NF-KB, and NF-KB does
 not play a positive role in the induction of
 apoptosis (10). In the case of ionizing radia-
 tion and daunorubicin, the activation of
 apoptosis appears to be initiated by ceramide
 production (11) and the cytotoxic effects of
 TNF have been reported to require ceramide
 activation (12). Ceramide alone has been
 shown to lead to apoptosis (13), but the de-
 tails of this apoptotic pathway are not fully
 understood. In each of these three cases, the
 apoptotic stimulus also leads to an inhibition
 of apoptosis through the activation of NF-KB.
 It should be noted that several groups have
 suggested that NF-KB may function pro-apop-
 totically under some conditions and in certain
 cell lines (14). The mechanism whereby NF-
 KB protects cells against apoptosis is presently
 unclear. Because cell killing by TNF and oth-
 er apoptotic agents is enhanced by the protein
 synthesis inhibitor CHX, the activation of
 NF-KB probably functions to transcriptionally
 up-regulate a gene or group of genes encoding
 proteins involved in protection against cell
 killing.
 Growing evidence indicates that a variety
 of anticancer agents kill through programmed
 cell death. Resistance to anticancer therapies
 appears to be mediated by resistance to apop-
 tosis (8). Our data show that several antican-
 cer agents may be less effective at inducing
 programmed cell death because of their con-
 comitant activation of NF-KB. Another can-
 cer therapy, etoposide, activates NF-KB (15)
 and our preliminary data indicate that cell
 killing by vincristine is augmented by the
 inhibition of NF-KB (4). Therefore, ap-
 proaches that inhibit nuclear translocation of
 NF-KB, including gene therapy delivery of the
 super-repressor IKBat or the use of a variety of
 agents that block NF-KB function (such as
 proteasome inhibitors), may prove to be high-
 ly beneficial in the treatment of tumors when
 combined with standard anticancer therapies.
 In fact, glucocorticoids, which are widely used
 as immune and inflammatory suppressants
 and inhibit NF-KB (16), are used as part of a
 therapy for certain hematological malignan-
 cies (17). It may be, therefore, that the func-
 tion of glucocorticoids in these therapies is to
 inhibit NF-KB, potentiating killing by the
 other chemotherapeutic compounds. Thus,
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 Fig. 2. NF-KB is a suppressor of TNF-induced
 apoptosis. (A) IL-1 pretreatment inhibits TNF +
 CHX-induced apoptosis in HT1 080V cells.
 HT1080V or HT10801 cells were preincubated
 with IL-1 K (10 ng/ml) (R&D Systems) for 5 hours as
 indicated (+pre-IL-1) or were left untreated. After
 the incubation, cells were treated with TNF-a at
 different concentrations (as indicated) and with
 CHX (10 ,ug/ml). Surviving cells were quantified by
 the crystal violet assay described above. (B) Ex-
 pression of the p50 and RelA/p65 NF-KB subunits
 restores cell resistance to TNF killing. HT1 0801
 cells (expressing the super-repressor IKBa) were
 either cotransfected with pcDNA3-lacZ (Invitro-
 gen) and pCMV-p65 (2 ,ug) and pCMV-p50 (2 ,ug)
 (hatched bars) or with lacZ and empty vectors
 (solid bars) by the lipofectamine protocol. After 40
 hours, cells were treated with different concentra-
 tions of TNF-a for an additional 24 hours. The
 results are from the mean ? SD of two experi-
 ments. X-Gal, 5-bromo-4-chloro-3-indoyl-3-D-
 galactoside.
 A B
 V I V V I
 1 2 3 45 6 7 8 910 1112 13 100-
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 Fig. 3. Activation of NF-KB by ionizing radiation or
 daunorubicin protects against apoptosis induced by 3 40
 these cancer therapies. (A) Daunorubicin and ionizing =
 radiation induce nuclear translocation of NF-KB. Either 2
 HT1 080V (V) or HT1 0801 (1) cells were treated with 1 pLM 20
 daunorubicin (Sigma) or 50 nM staurosporine (Sigma) or
 w re irradiated [at 5 grays (Gy)] for the indicated times. 0 0. 0 1 2 0.1 02 . 2
 EMSA was performed as previously described (21). Daunorubicin (gM)
 Lanes 1 through 5, daunorubicin; lanes 6 through 9, C
 staurosporine; and lanes 10 through 13, ionizing radia- 100
 tion. (B and C) The overexpression of super-repressor
 IKBa enhanced cell killing by daunorubicin and ionizing 80_
 radiation. (B) HT1 080V cells (solid bars) or HT1 0801 cells *
 (hatched bars) were treated with the indicated concen- g 60-
 tration of daunorubicin for 24 hours. Cell survival was *
 assayed as described in Fig. 1. Data are from the mean of X 40 X
 four separate experiments. (C) Five hundred HT1 080V or
 HT1 0801 cells were plated in six-well plates, and 24 hours 20
 later the cells were exposed to ionizing radiation at the
 indicated doses. Cell clones were counted after 14 days. 0-
 Each experimental group was performed in triplicate. The 0 2.5 5 10
 results shown here represent three independent experi- Ionizing radiation (Gy)
 ments and are expressed as the mean ? SD.
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 tion in the presence of apoptotic stimuli may
 lower the anti-apoptotic threshold of tumors
 to provide a more effective treatment against
 resistant forms of cancer. Additionally, the
 inhibition of NF-KB function in association
 with TNF treatment may broaden the limited
 ability of this cytokine to function in an anti-
 tumor manner.
 Note added in proof. Wu et al. ( 18) recent-
 ly demonstrated that NF-KB blocks apop-
 tosis in B cells.
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 Suppression of TNF-Ot-Induced
 Apoptosis by NF-KB
 Daniel J. Van Antwerp, Seamus J. Martin,* Tal Kafri,
 Douglas R. Green, Inder M. Vermat
 Tumor necrosis factor (x (TNF-oL) signaling gives rise to a number of events, including
 activation of transcription factor NF-KB and programmed cell death (apoptosis). Previous
 studies of TNF-cx signaling have suggested that these two events occur independently.
 The sensitivity and kinetics of TNF-cx-induced apoptosis are shown to be enhanced in
 a number of cell types expressing a dominant-negative IKBcx (IKBoxM). These findings
 suggest that a negative feedback mechanism results from TNF-a signaling in which
 NF-KB activation suppresses the signals for cell death.
 The relation between TNF-ot signals for
 NF-KB activation and apoptosis suggests that
 the two pathways are independent, diverging
 early in the TNF-cx signaling cascade (1).
 Because TNF-o,-induced apoptosis is en-
 hanced in the absence of de novo RNA or
 protein synthesis (2), and NF-KB rapidly ac-
 tivates target gene transcription upon TNF-ox
 stimulation, we investigated whether the ab-
 sence of NF-KB-induced genes alone might
 enhance TNF-oa-induced apoptosis. To test
 this hypothesis on various cell types, we gen-
 erated a transdominant-negative mutant of
 IKBa (3). Many signal transduction pathways
 resulting in NF-KB activation culminate in a
 serine phosphorylation of IKBa on residues 32
 and 36 (4). Phosphorylation of the COOH-
 terminal PEST sequence has been implicated
 in constitutive tumover of IKBo (5). We
 combined the NH2- and COOH-terminal
 phosphorylation mutants into a single
 cDNA (IKBoM) and examined its ability to
 inhibit NF-KB signaling. We then generated
 stable transformants expressing IKBoaM (6)
 in primary mouse and human fibroblasts, a
 human lymphoma cell line (Jurkat), and a
 well-characterized TNF-o -resistant cell line
 (T24, human bladder carcinoma) (7).
 Infection with IKBBaM retrovirus resulted
 in a loss of NF-KB inducibility (Figs. 1 and 2).
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 Each cell line represented pools of infected
 cells to avoid artifacts arising from clonal
 analysis. Human embryo fibroblasts (HEF) ei-
 ther alone or expressing IKBoxM were stimu-
 lated for various time periods to examine NF-
 KB inducibility (Fig. 1). Protein immunoblot-
 ting (8) (Fig. IA) shows the expression of
 murine IKBotM, which migrated faster on
 SDS-polyacrylamide gel electrophoresis
 (PAGE) than the endogenous human IKBot
 (4). The expression of IKBotM was only mod-
 estly higher than that of endogenous IKBox,
 demonstrating the abilityof IKBcXM to inhibit
 NF-KB. After TNF-o stimulation in both
control and IKBoxM cells, endogenous IKBcx
 was phosphorylated and degraded with similar
 kinetics, demonstrating that in IKBoaM-ex-
 pressing cell lines, the signal transduction
 pathway upstream of NF-KB activation was
 not blocked (Fig. IA). IKBxM was not de-
 graded, presumably because it was not phos-
 phorylated. Because the IKBot gene is induced
 Table 1. Annexin V-FITC flow cytometric analy-
 sis of Jurkat cells stably transduced with IKBcxM.
 Normal or IKBoxM Jurkat cells were treated with
 TNF-u. (100 ng/ml) for the indicated times and
 stained with FITC-labeled annexin V. The cells
 were then analyzed by flow cytometry as de-
 scribed (14). Five thousand cells were analyzed
 under each condition.
 Percent annexin V
 Time (hours) binding
 Control IKBoxM
 0 10.4 12.3
 3 13.7 26.6
 7 24.1 39.9
 24 28.2 62.3
 48 30.1 86.3
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